Sekine L, et al. - Given that autologous transplantation continues to be the cornerstone for younger and fit multiple myeloma patients, and frontline induction therapy before transplantation can influence post-transplant results, researchers intended to compare lenalidomide to other regimens in this setting. A systematic review and network meta-analysis of 21 clinical trial publications was performed, recruiting 6,474 subjects and comparing 11 different treatment frontline setting regimens regarding survival, response and safety outcomes. Current recommendations on combined immunomodulatory drugs and proteasome inhibitors frontline regimens (in triplets) in transplant-eligible multiple myeloma patients were supported in this analysis. When compared to bortezomib/thalidomide protocols, study results showed the favorable performance of lenalidomide in overall and progression-free survival.